综述

m6A甲基化修饰在急性肾损伤中的研究进展

  • 唐立丽 ,
  • 王昕宇 ,
  • 张杰 ,
  • 赵悦 ,
  • 李小悦
展开
  • 遵义医科大学第五附属(珠海)医院急诊科、重症医学科 (广东 珠海 519100 )

收稿日期: 2023-08-10

  网络出版日期: 2024-03-06

基金资助

国家自然科学基金(81960361);广东省医学科研基金(B2023238)

Research progress on the relationship between m6A methylation modification and acute kidney injury

  • Lili TANG ,
  • Xinyu WANG ,
  • Jie ZHANG ,
  • Yue ZHAO ,
  • Xiaoyue LI
Expand
  • Department of Critical Care Medicine and emergency department,the Fifth Affiliated (Zhuhai) ospital of Zunyi Medical University,Zhuhai 519000,China

Received date: 2023-08-10

  Online published: 2024-03-06

摘要

急性肾损伤因高发病率、高病死率、高治疗费用已然成为全球性重要公共健康问题,其发病机制复杂、治疗策略有限,深入探索其病理生理机制、寻找临床治疗的潜在靶点具有重要意义。N6-甲基腺嘌呤(m6A)甲基化是真核生物中最为普遍和高度保守的表观遗传修饰,是由m6A甲基转移酶、去甲基化酶和阅读蛋白共同调控RNA的剪接、出核、翻译、稳定性和高级结构的动态可逆过程。研究表明m6A甲基化修饰在急性肾损伤的发生发展中发挥重要调节作用,有望成为治疗急性肾损伤的有效靶点。本文就m6A在急性肾损伤中的调控作用及未来可能的研究方向进行综述。

本文引用格式

唐立丽 , 王昕宇 , 张杰 , 赵悦 , 李小悦 . m6A甲基化修饰在急性肾损伤中的研究进展[J]. 实用医学杂志, 2024 , 40(2) : 278 -282 . DOI: 10.3969/j.issn.1006-5725.2024.02.026

Abstract

Acute kidney injury(AKI) is a global public health problem with high morbidity, high mortality and costly treatment cost. The pathogenesis of AKI is very complex, and the treatment strategies for AKI are limited, then it is very matter to explore the pathophysiological mechanism and potential therapeutic targets of acute kidney injury. N6-methyladenosine(m6A) is the most abundant and extremely conservative epigenetic modification in eukaryotic, which is a dynamic and reversible process involving in splicing, nuclear export, translation, stability, and higher structure of RNA, and regulated by three regulatory factors: methyltransferase, demethylase and methylated reading protein. Current studies have found that m6A plays an important regulatory role in AKI and can be a potential therapeutic target for AKI. In this review, we provide a brief description of m6A and summarize the impact of m6A on AKI and possible future study directions for this research.

参考文献

1 RONCO C, BELLOMO R, KELLUM J A. Acute kidney injury[J]. Lancet, 2019,394(10212):1949-1964. doi:10.1016/s0140-6736(19)32563-2
2 HOSTE E A, BAGSHAW S M, BELLOMO R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study[J]. Intensive Care Med, 2015,41(8):1411-1423. doi:10.1007/s00134-015-3934-7
3 FU Y, DOMINISSINI D, RECHAVI G, et al. Gene expression regulation mediated through reversible m(6)A RNA methylation[J]. Nat Rev Genet, 2014,15(5):293-306. doi:10.1038/nrg3724
4 SU S, LI S, DENG T, et al. Cryo-EM structures of human m(6)A writer complexes[J]. Cell Res, 2022,32(11):982-994. doi:10.1038/s41422-022-00725-8
5 WANG X, FENG J, XUE Y, et al. Corrigendum: Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex[J]. Nature, 2017,542(7640):260. doi:10.1038/nature21073
6 HUANG Q, MO J, LIAO Z, et al. The RNA m(6)A writer WTAP in diseases: structure, roles, and mechanisms[J]. Cell Death Dis, 2022,13(10):852. doi:10.1038/s41419-022-05268-9
7 PATIL D P, CHEN C K, PICKERING B F, et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression[J]. Nature, 2016,537(7620):369-373. doi:10.1038/nature19342
8 JIANG X, LIU B, NIE Z, et al. The role of m6A modification in the biological functions and diseases[J]. Signal Transduct Target Ther, 2021,6(1):74. doi:10.1038/s41392-020-00450-x
9 FANG X, LI M, YU T, et al. Reversible N6-methyladenosine of RNA: The regulatory mechanisms on gene expression and implications in physiology and pathology[J]. Genes Dis, 2020,7(4):585-597. doi:10.1016/j.gendis.2020.06.011
10 JIA G, FU Y, ZHAO X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J]. Nat Chem Biol, 2011,7(12):885-887. doi:10.1038/nchembio.687
11 QU J, YAN H, HOU Y, et al. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential[J]. J Hematol Oncol, 2022,15(1):8. doi:10.1186/s13045-022-01224-4
12 CHEN Z, QI M, SHEN B, et al. Transfer RNA demethylase ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs[J]. Nucleic Acids Res, 2019,47(5):2533-2545. doi:10.1093/nar/gky1250
13 RIES R J, ZACCARA S, KLEIN P, et al. m(6)A enhances the phase separation potential of mRNA[J]. Nature, 2019,571(7765):424-428. doi:10.1038/s41586-019-1374-1
14 CHEN L, GAO Y, XU S, et al. N6-methyladenosine reader YTHDF family in biological processes: Structures, roles, and mechanisms[J]. Front Immunol, 2023,14:1162607. doi:10.3389/fimmu.2023.1162607
15 WIDAGDO J, ANGGONO V, WONG J J. The multifaceted effects of YTHDC1-mediated nuclear m(6)A recognition[J]. Trends Genet, 2022,38(4):325-332. doi:10.1016/j.tig.2021.11.005
16 HSU P J, ZHU Y, MA H, et al. Ythdc2 is an N(6)-methyladenosine binding protein that regulates mammalian spermatogenesis[J]. Cell Res, 2017,27(9):1115-1127. doi:10.1038/cr.2017.99
17 HUANG H, WENG H, SUN W, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation[J]. Nat Cell Biol, 2018,20(3):285-295. doi:10.1038/s41556-018-0045-z
18 ALARCON C R, GOODARZI H, LEE H, et al. HNRNPA2B1 Is a Mediator of m(6)A-Dependent Nuclear RNA Processing Events[J]. Cell, 2015,162(6):1299-1308. doi:10.1016/j.cell.2015.08.011
19 LIU N, DAI Q, ZHENG G, et al. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions[J]. Nature, 2015,518(7540):560-564. doi:10.1038/nature14234
20 MEYER K D, PATIL D P, ZHOU J, et al. 5' UTR m(6)A Promotes Cap-Independent Translation[J]. Cell, 2015,163(4):999-1010. doi:10.1016/j.cell.2015.10.012
21 SUN Y, JIN D, ZHANG Z, et al. N6-methyladenosine (m6A) methylation in kidney diseases: Mechanisms and therapeutic potential[J]. Biochim Biophys Acta Gene Regul Mech, 2023,1866(4):194967. doi:10.1016/j.bbagrm.2023.194967
22 李晶,陆芹芹,崔艳飞. 血清PGC-1α水平在脓毒症致急性肾损伤诊断中的价值[J]. 实用医学杂志, 2023,39(4):471-475. doi:10.3969/j.issn.1006-5725.2023.04.015
23 LIU B, AO S, TAN F, et al. Transcriptomic analysis and laboratory experiments reveal potential critical genes and regulatory mechanisms in sepsis-associated acute kidney injury[J]. Ann Transl Med, 2022,10(13):737. doi:10.21037/atm-22-845
24 WANG J N, WANG F, KE J, et al. Inhibition of METTL3 attenuates renal injury and inflammation by alleviating TAB3 m6A modifications via IGF2BP2-dependent mechanisms[J]. Sci Transl Med, 2022,14(640):eabk2709. doi:10.1126/scitranslmed.abk2709
25 PAN J, XIE Y, LI H, et al. mmu-lncRNA 121686/hsa-lncRNA 520657 induced by METTL3 drive the progression of AKI by targeting miR-328-5p/HtrA3 signaling axis[J]. Mol Ther, 2022,30(12):3694-3713. doi:10.1016/j.ymthe.2022.07.014
26 HU C, ZHANG B, ZHAO S. METTL3-mediated N6-methyladenosine modification stimulates mitochondrial damage and ferroptosis of kidney tubular epithelial cells following acute kidney injury by modulating the stabilization of MDM2-p53-LMNB1 axis[J]. Eur J Med Chem, 2023,259:115677. doi:10.1016/j.ejmech.2023.115677
27 ZhU S, LU Y. Dexmedetomidine Suppressed the Biological Behavior of HK-2 Cells Treated with LPS by Down-Regulating ALKBH5[J]. Inflammation, 2020,43(6):2256-2263. doi:10.1007/s10753-020-01293-y
28 YU F, ZHU A C, LIU S, et al. RBM33 is a unique m(6)A RNA-binding protein that regulates ALKBH5 demethylase activity and substrate selectivity[J]. Mol Cell, 2023,83(12):2003-2019. doi:10.1016/j.molcel.2023.05.010
29 MAO Y, JIANG F, XU X J, et al. Inhibition of IGF2BP1 attenuates renal injury and inflammation by alleviating m6A modifications and E2F1/MIF pathway[J]. Int J Biol Sci, 2023,19(2):593-609. doi:10.7150/ijbs.78348
30 ZHANG S, GUAN X, LIU W, et al. YTHDF1 alleviates sepsis by upregulating WWP1 to induce NLRP3 ubiquitination and inhibit caspase-1-dependent pyroptosis[J]. Cell Death Discov, 2022,8(1):244. doi:10.1038/s41420-022-00872-2
31 邹丛,胡红林,涂云明,等. 吡格列酮保护糖尿病大鼠肾缺血再灌注损伤的实验研究[J]. 实用医学杂志, 2020,36(4):434-439. doi:10.3969/j.issn.1006-5725.2020.04.003
32 陈康,周向军,程帆. N6-甲基腺苷甲基化与肾脏缺血再灌注损伤关系的研究进展[J]. 中华实验外科杂志, 2021,38(12):2542-2544. doi:10.3760/cma.j.cn421213-20210225-00167
33 MENG F, LIU Y, CHEN Q, et al. METTL3 contributes to renal ischemia-reperfusion injury by regulating Foxd1 methylation[J]. Am J Physiol Renal Physiol, 2020,319(5):F839-F847. doi:10.1152/ajprenal.00222.2020
34 XU Y, YUAN X D, WU J J, et al. The N6-methyladenosine mRNA methylase METTL14 promotes renal ischemic reperfusion injury via suppressing YAP1[J]. J Cell Biochem, 2020,121(1):524-533. doi:10.1002/jcb.29258
35 XING J, HE Y C, WANG K Y, et al. Involvement of YTHDF1 in renal fibrosis progression via up-regulating YAP[J]. FASEB J, 2022,36(2):e22144. doi:10.1096/fj.202100172rr
36 熊冰瑶,康志娟,李志辉. 脂肪量和肥胖相关蛋白在人肾小管上皮细胞缺血再灌注损伤中的作用[J]. 中华实用儿科临床杂志, 2022,37(8):626-630. doi:10.3760/cma.j.cn101070-20210116-00070
37 ZHUANG C, ZHUANG C, LUO X, et al. N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1alpha signalling axis[J]. J Cell Mol Med, 2019,23(3):2163-2173. doi:10.1111/jcmm.14128
38 YANG Y, LI Q, LING Y, et al. m6A eraser FTO modulates autophagy by targeting SQSTM1/P62 in the prevention of canagliflozin against renal fibrosis[J]. Front Immunol, 2022,13:1094556. doi:10.3389/fimmu.2022.1094556
39 CHEN J, XU C, YANG K, et al. Inhibition of ALKBH5 attenuates I/R-induced renal injury in male mice by promoting Ccl28 m6A modification and increasing Treg recruitment[J]. Nat Commun, 2023,14(1):1161. doi:10.1038/s41467-023-36747-y
40 MEHTA R L, BURDMANN E A, CERDA J, et al. Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study[J]. Lancet, 2016,387(10032):2017-2025. doi:10.1016/s0140-6736(16)30240-9
41 HOLDITCH S J, BROWN C N, LOMBARDI A M, et al. Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury[J]. Int J Mol Sci, 2019,20(12):3011. doi:10.3390/ijms20123011
42 LI C M, LI M, ZHAO W B, et al. Alteration of N6-Methyladenosine RNA Profiles in Cisplatin-Induced Acute Kidney Injury in Mice[J]. Front Mol Biosci, 2021,8:654465. doi:10.3389/fmolb.2021.654465
43 ZHOU P, WU M, YE C, et al. Meclofenamic acid promotes cisplatin-induced acute kidney injury by inhibiting fat mass and obesity-associated protein-mediated m(6)A abrogation in RNA[J]. J Biol Chem, 2019,294(45):16908-16917. doi:10.1074/jbc.ra119.011009
44 LI S, ZHOU H, LIANG Y, et al. Integrated analysis of transcriptome-wide m(6)A methylation in a Cd-induced kidney injury rat model[J]. Ecotoxicol Environ Saf, 2023,256:114903. doi:10.1016/j.ecoenv.2023.114903
45 WANG J, ISHFAQ M, XU L, et al. METTL3/m(6)A/miRNA-873-5p Attenuated Oxidative Stress and Apoptosis in Colistin-Induced Kidney Injury by Modulating Keap1/Nrf2 Pathway[J]. Front Pharmacol, 2019,10:517. doi:10.3389/fphar.2019.00517
46 WAN S J, HUA Q, XING Y J, et al. Decreased Urine N6-methyladenosine level is closely associated with the presence of diabetic nephropathy in type 2 diabetes mellitus[J]. Front Endocrinol (Lausanne), 2022,13:986419. doi:10.3389/fendo.2022.986419
文章导航

/